1,80 $
9,09 %vorgestern
Nasdaq, 1. März, 22:00 Uhr
ISIN
US76200L3096
Symbol
RZLT
Berichte

Rezolute Inc Aktie News

Neutral
GlobeNewsWire
19 Tage alt
Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025
Neutral
GlobeNewsWire
etwa ein Monat alt
REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition of Daron Evans, MS, MBA, to its leadership team as Chief Financial Officer as well as the grant of share options as a material inducement for...
Neutral
GlobeNewsWire
etwa ein Monat alt
REDWOOD CITY, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the innovative medicine designation, the Innovation Passport, to RZ35...
Neutral
GlobeNewsWire
3 Monate alt
Company anticipates completing enrollment by the end of 2024 and reporting topline results in mid-year 2025 Company anticipates completing enrollment by the end of 2024 and reporting topline results in mid-year 2025
Neutral
GlobeNewsWire
3 Monate alt
REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the completion of enrollment in its RZ402 Phase 2 study in diabetic macular edema (“DME”).
Neutral
GlobeNewsWire
4 Monate alt
REDWOOD CITY, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the management team will participate in BTIG's 3rd Annual Ophthalmology Day, taking place virtually on November 27th.
Neutral
GlobeNewsWire
4 Monate alt
REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the first quarter of fiscal 2024 ended September 30, 2023.
Positiv
Seeking Alpha
4 Monate alt
Rezolute is a clinical-stage biotechnology company focused on metabolic diseases related to glucose control. Their lead asset, RZ358, is a monoclonal antibody being developed as a treatment for hyperinsulinism, a condition characterized by excessive insulin production. The Company is trading for 50% of cash, about to initiate a phase 3 study in an ultra-orphan indication, with significant poten...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen